GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Personalis Inc (STU:04X) » Definitions » Institutional Ownership

Personalis (STU:04X) Institutional Ownership : 34.69% (As of May. 23, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Personalis Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Personalis's institutional ownership is 34.69%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Personalis's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Personalis's Float Percentage Of Total Shares Outstanding is 52.92%.


Personalis Institutional Ownership Historical Data

The historical data trend for Personalis's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Personalis Institutional Ownership Chart

Personalis Historical Data

The historical data trend for Personalis can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 50.29 48.50 47.16 43.89 38.33 39.97 37.39 36.49 33.97 34.69

Personalis Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Personalis (STU:04X) Business Description

Traded in Other Exchanges
Address
6600 Dumbarton Circle, Fremont, CA, USA, 94555
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions.

Personalis (STU:04X) Headlines

No Headlines